<DOC>
	<DOC>NCT02321878</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.</brief_summary>
	<brief_title>Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtained before any studyrelated activities (Studyrelated activities are any procedure related to recording of data according to the protocol) Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral antidiabetes drug) other than SU (sulfonylurea) Male or female, no age limitation Previous participation in this study or NN22113772 Participation is defined as informed consent obtained for this study or enrolment for NN22113772 Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>